晚期皮肤癌的新型疗法。
Novel therapies for advanced skin carcinomas.
作者信息
Modrakowska Paulina, Balik Karolina, Maj Małgorzata, Bajek Anna
机构信息
Department of Tissue Engineering, The Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.
出版信息
Postepy Dermatol Alergol. 2020 Oct;37(5):660-670. doi: 10.5114/ada.2020.100479. Epub 2020 Nov 7.
Abstract
Advanced skin carcinomas are a serious therapeutic problem. The statistical analysis shows a continuous increase in the incidence of both melanoma and non-melanoma skin cancers. Traditional therapies are characterized by low effectiveness and patients overall survival is not affected by them. By understanding the molecular pathways that lead to the neoplastic transformation and thanks to the knowledge of the immune system, it is possible to use personalized medicine in novel therapies for advanced skin carcinomas.
摘要
晚期皮肤癌是一个严重的治疗难题。统计分析表明，黑色素瘤和非黑色素瘤皮肤癌的发病率都在持续上升。传统疗法的特点是疗效不佳，对患者的总体生存率没有影响。通过了解导致肿瘤转化的分子途径，并借助对免疫系统的认识，有可能在晚期皮肤癌的新型疗法中使用个性化医疗。
相似文献
1
Novel therapies for advanced skin carcinomas.
Postepy Dermatol Alergol. 2020 Oct;37(5):660-670. doi: 10.5114/ada.2020.100479. Epub 2020 Nov 7.
2
[Personalized medicine in the treatment of periocular tumors : Targeted treatment and use of immune checkpoint inhibitors].
Ophthalmologe. 2020 Jun;117(6):521-527. doi: 10.1007/s00347-019-01034-z.
3
Current trends in the treatment of malignant melanoma.
Neoplasma. 2016;63(3):333-41. doi: 10.4149/301_151015N533.
4
Epidemiology of basal cell carcinomas and squamous cell carcinomas in a Department of Dermatology: a 5 year review.
An Bras Dermatol. 2012 Mar-Apr;87(2):212-9. doi: 10.1590/s0365-05962012000200004.
5
Non-melanoma skin cancer in Portuguese kidney transplant recipients - incidence and risk factors.
An Bras Dermatol. 2016 Jul-Aug;91(4):455-62. doi: 10.1590/abd1806-4841.20164891.
6
Evolving Role of Systemic Therapies in Non-melanoma Skin Cancer.
Clin Oncol (R Coll Radiol). 2019 Nov;31(11):759-768. doi: 10.1016/j.clon.2019.08.011. Epub 2019 Sep 12.
7
[Possible immunotherapies of skin cancers].
Magy Onkol. 2019 Sep 18;63(3):239-245. Epub 2019 Jul 25.
8
[Immunotherapy for malignant melanoma].
Internist (Berl). 2020 Jul;61(7):669-675. doi: 10.1007/s00108-020-00812-1.
9
Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years.
JAMA. 2005 Aug 10;294(6):681-90. doi: 10.1001/jama.294.6.681.
10
UV-Induced Molecular Signaling Differences in Melanoma and Non-melanoma Skin Cancer.
Adv Exp Med Biol. 2017;996:27-40. doi: 10.1007/978-3-319-56017-5_3.
引用本文的文献
1
Diagnosis of Skin Cancer: From the Researcher Bench to the Patient's Bedside.
J Clin Med. 2024 Mar 7;13(6):1523. doi: 10.3390/jcm13061523.
2
Incidence of different types of cancer in the follow-up period after primary diagnosis and treatment of melanoma. Single-centre 4-year follow-up on a population of 709 patients.
Postepy Dermatol Alergol. 2023 Jun;40(3):416-420. doi: 10.5114/ada.2023.127545. Epub 2023 Jun 21.
本文引用的文献
1
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
N Engl J Med. 2018 Jul 26;379(4):341-351. doi: 10.1056/NEJMoa1805131. Epub 2018 Jun 4.
2
Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial.
Cancer. 2018 May 15;124(10):2169-2173. doi: 10.1002/cncr.31346. Epub 2018 Mar 26.
3
Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib.
Oncotarget. 2016 Jul 13;9(15):12408-12417. doi: 10.18632/oncotarget.10589. eCollection 2018 Feb 23.
4
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Genome Med. 2017 Apr 19;9(1):34. doi: 10.1186/s13073-017-0424-2.
5
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol. 2017 Apr;18(4):435-445. doi: 10.1016/S1470-2045(17)30180-8. Epub 2017 Mar 9.
6
Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human Knock-In Mice.
Mol Cancer Ther. 2017 May;16(5):861-870. doi: 10.1158/1535-7163.MCT-16-0665. Epub 2017 Mar 6.
7
Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.
Cancer Discov. 2016 Jul;6(7):703-13. doi: 10.1158/2159-8290.CD-16-0146. Epub 2016 Apr 22.
8
Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
JAMA Dermatol. 2016 Jul 1;152(7):816-24. doi: 10.1001/jamadermatol.2016.0780.
9
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
J Am Acad Dermatol. 2016 Jul;75(1):113-125.e5. doi: 10.1016/j.jaad.2016.02.1226. Epub 2016 Apr 7.
10
Defining locally advanced basal cell carcinoma and integrating smoothened inhibitors into clinical practice.
Curr Opin Oncol. 2016 Mar;28(2):180-4. doi: 10.1097/CCO.0000000000000259.
Zotero 插件